Newron Pharmaceuticals SpA (NP5) Financial Statements
Newron Pharmaceuticals SpA Financial Overview
Newron Pharmaceuticals SpA's market cap is currently $207.06M. The company's EPS TTM is $-1.46; its P/E ratio is -6.68; Newron Pharmaceuticals SpA is estimated to report earnings on March 16, 2027, and the estimated EPS forecast is $-0.77. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 19.13M | $ 51.39M | $ 9.06M | $ 6.09M | $ 5.76M |
| Gross Profit | $ 19.13M | $ 51.39M | $ 9.06M | $ 6.09M | $ 5.76M |
| Operating Income | $ -4.70M | $ 26.17M | $ -11.63M | $ -13.30M | $ -12.36M |
| EBITDA | $ -4.55M | $ 25.94M | $ -11.83M | $ -13.32M | $ -11.76M |
| Net Income | $ -13.24M | $ 15.84M | $ -16.22M | $ -17.49M | $ -14.90M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 28.85M | $ 9.83M | $ 12.60M | $ 22.77M | $ 34.59M |
| Total Assets | $ 40.02M | $ 63.91M | $ 25.87M | $ 37.20M | $ 50.49M |
| Total Debt | $ 38.13M | $ 50.47M | $ 48.41M | $ 45.66M | $ 43.08M |
| Net Debt | $ 25.96M | $ 43.54M | $ 42.08M | $ 32.24M | $ 18.06M |
| Total Liabilities | $ 51.15M | $ 62.45M | $ 55.77M | $ 51.23M | $ 47.38M |
| Stockholders' Equity | $ -11.13M | $ 1.46M | $ -29.91M | $ -14.03M | $ 3.11M |
| Cash Flow | |||||
| Free Cash Flow | $ 32.51M | $ -17.63M | $ -10.15M | $ -11.11M | $ -11.46M |
| Operating Cash Flow | $ 32.56M | $ -17.61M | $ -10.14M | $ -11.09M | $ -11.45M |
| Investing Cash Flow | $ -13.75M | $ 3.16M | $ 3.25M | $ -317.00K | $ 8.42M |
| Financing Cash Flow | $ -13.52M | $ 15.05M | $ -192.00K | $ -186.00K | $ 14.83M |
Currency in EUR